Fluconazole-Induced Stevens–Johnson Syndrome in a Type 2 Diabetic Male: A Case Report
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
1 Dey 2026
,
Page 1-6
https://doi.org/10.22037/ijmtfm.v16.51004
Abstract
Background: Stevens–Johnson Syndrome (SJS) is a rare but potentially life-threatening mucocutaneous hypersensitivity reaction, most commonly induced by drugs. Fluconazole, an antifungal agent widely used to treat candidiasis, is infrequently associated with SJS.
Case Presentation: We report a case of a 37-year-old male with Type 2 Diabetes Mellitus admitted with multiple oral ulcers, erythematous genital lesions, and excoriation of skin over hands and feet. He had been diagnosed with oral candidiasis and candidal balanitis five days earlier and was on oral Fluconazole 150 mg daily. On admission, the dose was escalated to 200 mg intravenously and subsequently to 250 mg. Within three days, the patient developed crusted erosions over the lips and buccal mucosa, with erythematous erosions over the genitalia, suggestive of SJS. Fluconazole was immediately withdrawn, and systemic corticosteroid therapy was initiated along with supportive care. The patient showed gradual improvement with re-epithelialization and complete recovery over one week.
Conclusion: This case highlights the rare occurrence of Fluconazole-induced SJS and underscores the importance of early recognition, prompt withdrawal of the offending drug, and multidisciplinary management to prevent morbidity.
- Fluconazole, Stevens–Johnson Syndrome, Adverse Drug Reaction, Antifungal, Diabetes
How to Cite
References
[1] Zimmerman D, Dang NH. Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions. In: Oncologic Critical Care. Cham: Springer International Publishing; 2019. p. 267–80. [DOI: 10.1007/978-3-319-74588-6_195]
[2] Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. J Invest Dermatol. 2017;137(9):2021–3. [DOI: 10.1016/j.jid.2017.05.010]
[3] Kocaaga A, Kocaaga M. A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis. Global Med Genet. 2025;12(3):100054. [DOI: 10.1016/j.gmg.2025.100054]
[4] Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011;50(2):221–4. [DOI: 10.1111/j.1365-4632.2010.04745.x]
[5] Peter JG, Lehloenya R, Dlamini S, Risma K, White KD, Konvinse KC, et al. Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. J Allergy Clin Immunol Pract. 2017;5(3):547–63. [DOI: 10.1016/j.jaip.2017.01.025]
[6] Kim EJ, Lim H, Park SY, Kim S, Yoon SY, Bae YJ, et al. Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen. Asia Pac Allergy. 2014;4(1):68–72. [DOI: 10.5415/apallergy.2014.4.1.68]
[7] Klimas N, Quintanilla-Dieck J, Vandergriff T. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. In: Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. London: Springer London; 2015. p. 259–69. [DOI: 10.1007/978-1-4471-6729-7_24]
[8] Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019 Sep 30;90(3-S):52–60. [DOI: 10.23750/abm.v90i3-S.8165]
[9] Yun J, Cai F, Lee FJ, Pichler WJ. T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pac Allergy. 2016;16(2):77–89. [DOI: 10.5415/apallergy.2016.6.2.77]
[10] Smelik M. Stevens-Johnson Syndrome: A Case Study. Perm J. 2002;6(1):29-31. [DOI: 10.7812/TPP/02.997]
[11] Tasker F, Smith SP, Mohd Mustapa MF, de Berker DAR. British Association of Dermatologists national clinical audit on the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Clin Exp Dermatol. 2024;49(8):810–6. [DOI: 10.1093/ced/llae010]
[12] Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017;153(6):514–22. [DOI: 10.1001/jamadermatol.2016.5668]
[13] Rao M, Young K, Jackson-Cowan L, Kourosh A, Theodosakis N. Post-Inflammatory Hypopigmentation: Review of the Etiology, Clinical Manifestations, and Treatment Options. J Clin Med. 2023;12(3):1243. [DOI: 10.3390/jcm12031243]
- Abstract Viewed: 116 times
- PDF Downloaded: 70 times